Future-proofing Gene Therapy Assays: Validation Strategies for Long-Term Success

In this webinar, industry experts from Precision for Medicine will provide insights on developing gene therapy immunogenicity assays focused on regulatory compliance, minimizing rework, and selecting the right assay approach.

Learn best practices for immunogenicity assay validation, cost-effective strategies, and future-proof assay designs. Compare neutralizing antibody (NAb) and total antibody (TAb) assays and their effects on timelines, costs, and clinical outcomes. Whether you’re in early development or optimizing later-phase trials, this session ensures your assays meet global standards, are robust, compliant, and scalable.

Topics covered

Understanding the regulatory landscape — key considerations for assay development
How to understand whether an IDE (Investigational Device Exemption) is required for assays used in your gene therapy trial
Comparative advantages of NAb and TAb assays
Best practices for assay validation — Practical strategies to ensure gene therapy immunogenicity assays are robust, reproducible, and compliant
Future-proofing your assay strategy — Balancing the need for a cost-effective assay to use in a Phase I that can be pivoted to support a later Phase study or post market testing without significant rework

Watch now.

FILL THE FORM BELOW

First Name *

Last Name *

Company Street Address *

Company Suite/Office *

Company Postal/Zip Code *

Company City *

Company State *

Company Country *

By submitting this content request, I have legitimate interest in the content and agree that Precision for Medicine, their partners, and the creators of any other content I have selected may contact me regarding news, products, and services that may be of interest to me.

YesNo